Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.

"R.B.D.: has grants from Astellas and GenomeDx and serves on advisory boards for Bayer and GenomeDx. D.G.: consults for Acceleron Pharma, Astellas/Medivation, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Innocrin (Viamet), Janssen Pharmaceuticals, Myovant Sciences (until 3/2017), OncLive, Pfizer, and Sanofi-Aventis. He receives research support from Acerta, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon/Valeant, Exelixis, Innocrin (Viamet), Janssen Pharmaceuticals, Millenium, Novartis, Pfizer, and Sanofi-Aventis. He has received an honorarium from Axess Oncology and speaking fees from Bayer, Exelixis, and Sanofi-Aventis. He served on the Capio Biosciences Inc Scientific Advisory Board until 4/1/2018. M.M.’s institution has received funds from Agensys, Bayer, Clovis, Janssen Pharmaceuticals, and Seattle Genetics. She has received travel funds from Clovis and Agensys. C.P.: is a paid investigator for clinical studies by Bayer and is part of Bayer’s speakers bureau."

"Beverly E. Barton, PhD, and Leonard Lionnet, PhD, CMPP, of ScioScientific, LLC, assisted with writing and editing this manuscript. The authors received no compensation from Bayer HealthCare Pharmaceuticals Inc. for their participation. No funded research is reported herein. R.B.D.: has grants from Astellas and GenomeDx and serves on advisory boards for Bayer and GenomeDx. D.G.: consults for Acceleron Pharma, Astellas/Medivation, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Innocrin (Viamet), Janssen Pharmaceuticals, Myovant Sciences (until 3/2017), OncLive, Pfizer, and Sanofi-Aventis. He receives research support from Acerta, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon/Valeant, Exelixis, Innocrin (Viamet), Janssen Pharmaceuticals, Millenium, Novartis, Pfizer, and Sanofi-Aventis. He has received an honorarium from Axess Oncology and speaking fees from Bayer, Exelixis, and Sanofi-Aventis. He served on the Capio Biosciences Inc Scientific Advisory Board until 4/1/2018. M.M.’s institution has received funds from Agensys, Bayer, Clovis, Janssen Pharmaceuticals, and Seattle Genetics. She has received travel funds from Clovis and Agensys. C.P.: is a paid investigator for clinical studies by Bayer and is part of Bayer’s speakers bureau."